[
  {
    "ts": null,
    "headline": "US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug",
    "summary": "The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug...",
    "url": "https://finnhub.io/api/news?id=eb1ca8799bf1cfda13e4f36220c376eca5ac17b500df0122a8c18879ee94d2cf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737916683,
      "headline": "US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug",
      "id": 132475742,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug...",
      "url": "https://finnhub.io/api/news?id=eb1ca8799bf1cfda13e4f36220c376eca5ac17b500df0122a8c18879ee94d2cf"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease",
    "summary": "Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment...",
    "url": "https://finnhub.io/api/news?id=438c5a13ceedd551bdfe8108030a6d2bcb07d7f6643e4914b1dc3c0d365802d9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737916444,
      "headline": "FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease",
      "id": 132475743,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment...",
      "url": "https://finnhub.io/api/news?id=438c5a13ceedd551bdfe8108030a6d2bcb07d7f6643e4914b1dc3c0d365802d9"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
    "summary": "Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment  Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment...",
    "url": "https://finnhub.io/api/news?id=471080e9b88b2032f0aa7ac565ef8a5b4c731b8b7c562f804c7e4d6e2419eef9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737916264,
      "headline": "FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
      "id": 132475745,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment  Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment...",
      "url": "https://finnhub.io/api/news?id=471080e9b88b2032f0aa7ac565ef8a5b4c731b8b7c562f804c7e4d6e2419eef9"
    }
  }
]